Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07YAR
|
|||
| Former ID |
DNCL002715
|
|||
| Drug Name |
NX-1207
|
|||
| Synonyms |
UNII-9L8TV1O7E0; 9L8TV1O7E0; Fexapotide [USAN]; CHEMBL3545061; 492447-54-8; L-Leucine, L-isoleucyl-L-alpha-aspartyl-L-glutaminyl-L-glutaminyl-L-valyl-L-leucyl-L-seryl-L-arginyl-L-isoleucyl-L-lysyl-L-leucyl-L-alpha-glutamyl-L-isoleucyl-L-lysyl-L-arginyl-L-cysteinyl-; L-isoleucyl-L-alpha-aspartyl-L-glutaminyl-L-glutaminyl-L-valyl-L-leucyl-L-seryl-L-arginyl-L-isoleucyl-L-lysyl-L-leucyl-L-alpha-glutamyl-L-isoleucyl-L-lysyl-L-arginyl-L-cysteinyl-L-leucine-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 3 | [1] | |
| Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 2 | [2] | ||
| Company |
Nymox Pharmaceutical
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C90H163N27O25S
|
|||
| Canonical SMILES |
CCC(C)C(C(=O)NC(CC(=O)O)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)CC)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C(C)CC)C(=O)NC(CCCCN)C(=O)NC(CCCNC(=N)N)C(=O)NC(CS)C(=O)NC(CC(C)C)C(=O)O)N
|
|||
| InChI |
1S/C90H163N27O25S/c1-15-48(12)68(95)84(137)110-60(41-67(123)124)81(134)105-55(28-31-64(93)119)75(128)104-56(29-32-65(94)120)77(130)115-69(47(10)11)85(138)111-59(39-45(6)7)80(133)113-62(42-118)82(135)103-54(27-23-37-101-90(98)99)76(129)116-70(49(13)16-2)86(139)108-52(25-19-21-35-92)73(126)109-58(38-44(4)5)79(132)106-57(30-33-66(121)122)78(131)117-71(50(14)17-3)87(140)107-51(24-18-20-34-91)72(125)102-53(26-22-36-100-89(96)97)74(127)114-63(43-143)83(136)112-61(88(141)142)40-46(8)9/h44-63,68-71,118,143H,15-43,91-92,95H2,1-14H3,(H2,93,119)(H2,94,120)(H,102,125)(H,103,135)(H,104,128)(H,105,134)(H,106,132)(H,107,140)(H,108,139)(H,109,126)(H,110,137)(H,111,138)(H,112,136)(H,113,133)(H,114,127)(H,115,130)(H,116,129)(H,117,131)(H,121,122)(H,123,124)(H,141,142)(H4,96,97,100)(H4,98,99,101)/t48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,68-,69-,70-,71-/m0/s1
|
|||
| InChIKey |
BROGCIMRGWLMOO-SJPGHYFNSA-N
|
|||
| CAS Number |
CAS 492447-54-8
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02003742) Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.